Spots Global Cancer Trial Database for stage iv hypopharyngeal squamous cell carcinoma ajcc v7

Every month we try and update this database with for stage iv hypopharyngeal squamous cell carcinoma ajcc v7 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer	NCT01810913	Oropharyngeal p... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha...	Atezolizumab Biospecimen Col... Cetuximab Cisplatin Computed Tomogr... Docetaxel Intensity-Modul... Laboratory Biom... Magnetic Resona... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck	NCT01064479	Metastatic Squa... Metastatic Squa... Metastatic Squa... Metastatic Squa... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Oral ... Stage IVC Oroph...	Carboplatin Cisplatin Docetaxel Erlotinib Hydro... Laboratory Biom... Pharmacological... Placebo Quality-of-Life...	18 Years -	M.D. Anderson Cancer Center
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer	NCT01810913	Oropharyngeal p... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha...	Atezolizumab Biospecimen Col... Cetuximab Cisplatin Computed Tomogr... Docetaxel Intensity-Modul... Laboratory Biom... Magnetic Resona... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	NCT00588770	Neck Squamous C... Recurrent Hypop... Recurrent Laryn... Recurrent Laryn... Recurrent Lip a... Recurrent Neck ... Recurrent Oral ... Recurrent Oroph... Recurrent Saliv... Recurrent Sinon... Salivary Gland ... Stage IV Hypoph... Stage IV Major ... Stage IVA Laryn... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Major... Stage IVA Oral ... Stage IVA Oroph... Stage IVA Sinon... Stage IVB Laryn... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Major... Stage IVB Oral ... Stage IVB Oroph... Stage IVB Sinon... Stage IVC Laryn... Stage IVC Laryn... Stage IVC Lip a... Stage IVC Major... Stage IVC Oral ... Stage IVC Oroph... Stage IVC Sinon... Tongue Carcinom...	Bevacizumab Carboplatin Cisplatin Docetaxel Fluorouracil Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck	NCT01064479	Metastatic Squa... Metastatic Squa... Metastatic Squa... Metastatic Squa... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Oral ... Stage IVC Oroph...	Carboplatin Cisplatin Docetaxel Erlotinib Hydro... Laboratory Biom... Pharmacological... Placebo Quality-of-Life...	18 Years -	M.D. Anderson Cancer Center
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer	NCT02567422	Head and Neck C... Head and Neck S... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage III Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IV Sinona...	Berzosertib Cisplatin Computed Tomogr... Laboratory Biom... Magnetic Resona... Positron Emissi... Radiation Thera...	18 Years -	National Cancer Institute (NCI)
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	NCT00588770	Neck Squamous C... Recurrent Hypop... Recurrent Laryn... Recurrent Laryn... Recurrent Lip a... Recurrent Neck ... Recurrent Oral ... Recurrent Oroph... Recurrent Saliv... Recurrent Sinon... Salivary Gland ... Stage IV Hypoph... Stage IV Major ... Stage IVA Laryn... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Major... Stage IVA Oral ... Stage IVA Oroph... Stage IVA Sinon... Stage IVB Laryn... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Major... Stage IVB Oral ... Stage IVB Oroph... Stage IVB Sinon... Stage IVC Laryn... Stage IVC Laryn... Stage IVC Lip a... Stage IVC Major... Stage IVC Oral ... Stage IVC Oroph... Stage IVC Sinon... Tongue Carcinom...	Bevacizumab Carboplatin Cisplatin Docetaxel Fluorouracil Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer	NCT02567422	Head and Neck C... Head and Neck S... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage III Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IV Sinona...	Berzosertib Cisplatin Computed Tomogr... Laboratory Biom... Magnetic Resona... Positron Emissi... Radiation Thera...	18 Years -	National Cancer Institute (NCI)
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer	NCT01254617	Recurrent Colon... Recurrent Hypop... Recurrent Laryn... Recurrent Laryn... Recurrent Lip a... Recurrent Metas... Recurrent Nasal... Recurrent Nasop... Recurrent Oral ... Recurrent Oroph... Recurrent Recta... Recurrent Saliv... Salivary Gland ... Squamous Cell C... Stage IV Hypoph... Stage IV Nasoph... Stage IVA Colon... Stage IVA Laryn... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Major... Stage IVA Nasal... Stage IVA Oral ... Stage IVA Oroph... Stage IVA Recta... Stage IVB Colon... Stage IVB Laryn... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Major... Stage IVB Nasal... Stage IVB Oral ... Stage IVB Oroph... Stage IVB Recta... Stage IVC Laryn... Stage IVC Laryn... Stage IVC Lip a... Stage IVC Major... Stage IVC Nasal... Stage IVC Oral ... Stage IVC Oroph... Tongue Carcinom...	Cetuximab Laboratory Biom... Lenalidomide	18 Years -	National Cancer Institute (NCI)
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer	NCT02567422	Head and Neck C... Head and Neck S... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage III Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IV Sinona...	Berzosertib Cisplatin Computed Tomogr... Laboratory Biom... Magnetic Resona... Positron Emissi... Radiation Thera...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: